SABCS

SABCS: Laser Ablation a Possible Alternative Breast Cancer Therapy

SABCS: Laser Ablation a Possible Alternative Breast Cancer Therapy

Laser ablation procedure shows promise on breast cancer tumors up to 2 cm in diameter, but more study is needed.

Impact of adding bevacizumab to presurgery chemotherapy for triple-negative breast cancer varies

By

The addition of bevacizumab to standard presurgery chemotherapy showed greater benefit in those whose cancers were classified as basal-like by gene expression assay, compared with those whose cancers were nonbasal-like.

Breast cancer has different biological characteristics and outcomes in men and women

By

Results from the largest series of male breast cancer cases ever studied shows improvement in male survival, but not equal to that seen in women with breast cancer.

Multigene test can predict risk of recurrence for women with ductal carcinoma in situ

By

A multigene test was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in situ (DCIS), according to data from a large study.

SABCS: Novel breast cancer drugs show promise in early trials

SABCS: Novel breast cancer drugs show promise in early trials

Pictilisib and pembrolizumab may prolong survival for women with advanced breast cancer, according to data from preliminary studies.

SABCS: Male breast cancer prognosis falls behind that for women

SABCS: Male breast cancer prognosis falls behind that for women

Although survival in male breast cancer has improved, treatment lags behind when compared to the cancer therapy women receive.

SABCS: Combined therapy can help younger breast cancer patients

SABCS: Combined therapy can help younger breast cancer patients

Adding tamoxifen to ovarian suppression doesn't provide a significant benefit over tamoxifen alone among premenopausal women with hormone receptor-positive early breast cancer, but the addition of ovarian suppression does benefit some of these women.

Trastuzumab benefit predicted by high levels of immune cells in breast cancer tumors

By

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab. These results were presented at the 2013 San Antonio Breast Cancer Symposium.

PIK3CA gene mutations make some breast cancers resistant to treatment

By

Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene. These results were presented at the 2013 San Antonio Breast Cancer Symposium.

Innovative clinical trial design is a new paradigm in breast cancer research

By

The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.

SABCS: Chemo combo aids triple-negative breast cancer

SABCS: Chemo combo aids triple-negative breast cancer

Two studies show increase in pathologic complete response with pre-op chemotherapy combinations.

SABCS: Drug decreases breast cancer risk in high-risk women

SABCS: Drug decreases breast cancer risk in high-risk women

Anastrozole reduces breast cancer risk by about half with few side effects, according to a study presented at the annual San Antonio Breast Cancer Symposium.

SABCS: Radiotherapy may be avoided in some breast cancers

SABCS: Radiotherapy may be avoided in some breast cancers

Radiotherapy has no benefit for some older women after surgery, and hormone treatment after surgery may provide a radiation alternative.

SABCS: Mammography benefit disparities reviewed

SABCS: Mammography benefit disparities reviewed

Apparent disparities between different reviews on the benefit of mammography screening on breast cancer mortality are mainly due to different denominators.

SABCS: Dual HER2 blockade in breast cancer examined

SABCS: Dual HER2 blockade in breast cancer examined

For human epidermal growth factor receptor 2 (HER2)-positive tumors, the combination of lapatinib and trastuzumab is better than either therapy alone, according to a study.

SABCS: Pathological Complete Chemo Response Higher in Young

SABCS: Pathological Complete Chemo Response Higher in Young

Compared with older women, those aged 35 or younger with triple-negative breast cancer are more likely to achieve a pathological complete response (pCR) after treatment with neoadjuvant chemotherapy.

SABCS: PD 0332991 + Letrozole studied in ER+ breast cancer

SABCS: PD 0332991 + Letrozole studied in ER+ breast cancer

Second study shows fulvestrant 500 mg prolongs survival versus 250 mg in advanced disease.

SABCS: Extending tamoxifen to 10 years beneficial in breast cancer

SABCS: Extending tamoxifen to 10 years beneficial in breast cancer

Reduced recurrence, mortality for women with estrogen receptor-positive early breast cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs